G N Okoli1, F Racovitan2, T Abdulwahid3, C H Righolt4, S M Mahmud5. 1. College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; George and Fay Yee Centre for Healthcare Innovation, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; Vaccine and Drug Evaluation Centre, University of Manitoba, Winnipeg, MB, Canada. 2. Vaccine and Drug Evaluation Centre, University of Manitoba, Winnipeg, MB, Canada. 3. George and Fay Yee Centre for Healthcare Innovation, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. 4. Vaccine and Drug Evaluation Centre, University of Manitoba, Winnipeg, MB, Canada; Community Health Sciences, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. 5. College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; Vaccine and Drug Evaluation Centre, University of Manitoba, Winnipeg, MB, Canada; Community Health Sciences, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. Electronic address: Salah.Mahmud@umanitoba.ca.
Abstract
BACKGROUND: We examined the influence of some factors on seasonal influenza vaccine effectiveness (VE) from test-negative design (TND) studies. METHODS: We systematically searched for full-text publications of VE against laboratory-confirmed influenza from TND studies in outpatient settings after the 2009/10 influenza pandemic. Two reviewers independently selected and extracted data from the included studies. We calculated pooled adjusted VE across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains, using an inverse variance, random-effects model. RESULTS: We included 76 full-text articles from 11,931 citations. VE estimates against A(H1N1)pdm09, A(H3N2), influenza B, and all influenza were homogenous and point pooled VE higher in the Southern hemisphere compared with the Northern hemisphere. The difference in pooled VE between the Southern and Northern hemispheres was statistically significant for A(H3N2), influenza B, and all influenza. A consistent pattern was observed in pooled VE across both hemispheres and continents, with the highest point pooled VE being against A(H1N1)pdm09, followed by influenza B, and lowest against A(H3N2). A nearly consistent pattern was observed in pooled VE across age groups in the Northern hemisphere, with pooled VE mostly decreasing with age. Point pooled VE against A(H3N2), influenza B, and all influenza were statistically significantly higher when vaccine was antigenically similar to circulating virus strains compared with when antigenically dissimilar. Similar pattern was observed in the Northern hemisphere, but there was a lack of data from the Southern hemisphere. CONCLUSION: Consistent patterns appear to exist in seasonal influenza VE across regions, age groups, and levels of vaccine antigenic similarity with circulating virus strains, with best vaccine performance against A(H1N1)pdm09 and worst against A(H3N2). The evidence highlights the need to consider geographical location, age, and vaccine antigenic similarity with circulating virus strains when designing and evaluating influenza VE studies.
BACKGROUND: We examined the influence of some factors on seasonal influenza vaccine effectiveness (VE) from test-negative design (TND) studies. METHODS: We systematically searched for full-text publications of VE against laboratory-confirmed influenza from TND studies in outpatient settings after the 2009/10 influenza pandemic. Two reviewers independently selected and extracted data from the included studies. We calculated pooled adjusted VE across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains, using an inverse variance, random-effects model. RESULTS: We included 76 full-text articles from 11,931 citations. VE estimates against A(H1N1)pdm09, A(H3N2), influenza B, and all influenza were homogenous and point pooled VE higher in the Southern hemisphere compared with the Northern hemisphere. The difference in pooled VE between the Southern and Northern hemispheres was statistically significant for A(H3N2), influenza B, and all influenza. A consistent pattern was observed in pooled VE across both hemispheres and continents, with the highest point pooled VE being against A(H1N1)pdm09, followed by influenza B, and lowest against A(H3N2). A nearly consistent pattern was observed in pooled VE across age groups in the Northern hemisphere, with pooled VE mostly decreasing with age. Point pooled VE against A(H3N2), influenza B, and all influenza were statistically significantly higher when vaccine was antigenically similar to circulating virus strains compared with when antigenically dissimilar. Similar pattern was observed in the Northern hemisphere, but there was a lack of data from the Southern hemisphere. CONCLUSION: Consistent patterns appear to exist in seasonal influenza VE across regions, age groups, and levels of vaccine antigenic similarity with circulating virus strains, with best vaccine performance against A(H1N1)pdm09 and worst against A(H3N2). The evidence highlights the need to consider geographical location, age, and vaccine antigenic similarity with circulating virus strains when designing and evaluating influenza VE studies.
Authors: Michelle Clarke; Suja M Mathew; Lynne C Giles; Alexia S Pena; Ian G Barr; Peter C Richmond; Helen S Marshall Journal: Vaccines (Basel) Date: 2022-04-29
Authors: Eric J Chow; Mark W Tenforde; Melissa A Rolfes; Benjamin Lee; Shreya Chodisetty; Julio A Ramirez; Alicia M Fry; Manish M Patel Journal: PLoS One Date: 2021-10-21 Impact factor: 3.240
Authors: Miranda J Delahoy; Lindsey Mortenson; Laura Bauman; Juan Marquez; Natasha Bagdasarian; Joseph Coyle; Kelsey Sumner; Nathaniel M Lewis; Adam S Lauring; Brendan Flannery; Manish M Patel; Emily T Martin Journal: MMWR Morb Mortal Wkly Rep Date: 2021-12-10 Impact factor: 17.586
Authors: Weiwen Liang; Timothy J C Tan; Yiquan Wang; Huibin Lv; Yuanxin Sun; Roberto Bruzzone; Chris K P Mok; Nicholas C Wu Journal: PLoS Pathog Date: 2022-09-26 Impact factor: 7.464
Authors: Jessie R Chung; Sara S Kim; Rebecca J Kondor; Catherine Smith; Alicia P Budd; Sara Y Tartof; Ana Florea; H Keipp Talbot; Carlos G Grijalva; Karen J Wernli; C Hallie Phillips; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Michael Reis; Krissy Moehling Geffel; Mary Patricia Nowalk; Juliana DaSilva; Lisa M Keong; Thomas J Stark; John R Barnes; David E Wentworth; Lynnette Brammer; Erin Burns; Alicia M Fry; Manish M Patel; Brendan Flannery Journal: MMWR Morb Mortal Wkly Rep Date: 2022-03-11 Impact factor: 17.586